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Abstract
The gene DMBT1 (deleted in malignant brain tumour-1) has been proposed to play a role in brain and
epithelial cancer, but shows unusual features for a classical tumour-suppressor gene. On the one hand, DMBT1
has been linked to mucosal protection, whereas, on the other, it potentially plays a role in epithelial
differentiation. Thus its function in a particular tissue is of mechanistic importance for its role in cancer.
Because the former function requires secretion to the lumen and the latter function may depend on its
presence in the extracellular matrix, we decided to investigate DMBT1 expression, location and its mode of
secretion during malignant transformation in colorectal cancer. Using human colorectal PC/AA cell lines and
tissue sections from individual patients, we have examined the expression of DMBT1 and its glycosylation
in the adenoma–carcinoma sequence leading to the adenocarcinoma phenotype.
Introduction
Changes in the glycosylation of a variety of glycoproteins,
includingmucins and tumour-suppressor-gene products, fea-
ture among the many studies designed to investigate the
mechanisms of malignant transformation in CRC (colorectal
cancer) at the molecular level [1–3].
The nature and mechanism leading to these defects is
poorly understood. Secreted and membrane-bound glyco-
proteins are produced continuously to create a mucosal sur-
face micro-environment, which functions as part of the
innate protective programme. Tumour cells modulate this
programme during proliferation and the development of in-
vasive phenotypes, and also in order to attain the ability
to metastasize. This implies that each stage of malignant
transformation will be associated with a different glycosyl-
ation profile and that the identification of antigenic struc-
tures among the different oligosaccharides present in the
glycoproteins may be used for tumour staging.
Among the glycoproteins that are synthesized and secreted
by intestinal epithelial cells are the mucins and a variety of
protective proteins, including tumour suppressor proteins.
DMBT1 (deleted in malignant brain tumour-1) is a potential
tumour-suppressor genewith tissue-specific cellular and sub-
cellular expression and which has been correlated with its
action in tumour development in brain and epithelial tumours
[4]. Little is known regarding the glycosylation of this mol-
ecule and whether it correlates with its cellular location and
protective function.
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The availability of cultured human colorectal cell lines es-
tablished as a model for the adenoma–carcinoma sequence [5]
provides the means to examine the role of selected glyco-
proteins that make a significant contribution to the structure
of the mucosal protective barrier and its battery of protective
proteins. These cell lines have been used to examine the
properties of DMBT1 in CRC.
Glycosylation and mucins in CRC
The surface epithelium of the intestinal tract is coated with
a protective layer of mucus. This mucus constitutes a physical
protective barrier between the tissue and the aggressive ex-
ternal environment, including the enteric microflora. Mucins
are themajor components inmucus and confer its rheological
properties such as elasticity, adherence and viscosity. They are
high-molecular-mass molecules and possess a large variety of
glycans.
A number of studies have shown altered glycosylation of
mucins in CRC [2,3,6]. These defects have been linked with
cellular growth, differentiation, transformation, adhesion and
invasive potential.
Expression ofMUC2 andMUC3, the genes encoding the
major mucins found in the normal intestinal tract, is strongly
diminished in colorectal adenocarcinomas, with concomitant
inductionofMUC5AC. In order to determine the importance
of mucins in the progression to CRC, knockout mice for
Muc2 were generated. This work showed that Muc2 can
regulate the formation of malignant tumours in the small
intestine and colon of these mice, and therefore functions as
a tumour suppressor [7].
Modifications of glycosylation are characteristic of CRC
cells, and a variety of cell-surface glycan antigens have been
identified.Colon cancer has been characterized by an increase
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in the expression of T [Galβ1→ 3-GalNAc-(N-acetylgalac-
tosamine)], Tn (GalNAcα1→ Ser/Thr), sialyl-Tn, sialyl-Lex
(Lewis x) and sialyl-Lea (Lewis a) antigens. It has been
shown that cells expressing these epitopes are resistant to
natural killer and cytotoxic T-cells and also metastasize more
readily. Expression of sialyl-Tn and sialyl-Lex antigens are
associated with a poorer survival rate of patients with colon
cancer, suggesting an important role for these glycan struc-
tures in the biology of CRC [2,3,6]. Based on these results, a
variety of screening markers for malignant transformation in
CRC and other cancers have been developed, including SSEA
(stage-specific embryonic antigen) and CA19.9. However,
not one of these alone has been sufficiently sensitive for the
detection of early cancer. They have been used to confirm
diagnosis and detect recurrence.
Recently, we have been able to identify a glycan repertoire
for each stage of the human gastrointestinal tract using NMR
and MS methods [8,9].
DMBT1: molecular properties and
relationship to CRC
DMBT1 is a secreted glycoprotein, which is believed tomedi-
ate mucosal homoeostasis and it has been proposed as a can-
didate tumour-suppressor gene and implicated in the devel-
opment of epithelial cancers through its down-regulation
[4]. The significance of the gene and its product was ini-
tially recognized with regard to its loss in brain tumours. A
role for the protein in the development of malignant disease
was suggested by its chromosomal location (10q25.3-26.1),
which frequently shows losses of heterozygosity in a range
of tumours. The high homology of its SRCR (scavenger re-
ceptor cysteine-rich) domains and SIDs (SRCR interspersed
domains), and their occurrence as multiple tandem repeats,
also represents a genomic structure that may be susceptible
to instability. Accordingly, it is believed that DMBT1 plays a
role in epithelial cancer development, including CRC [10].
Cloning of the protein demonstrated a number of forms.
The N-terminus contains up to 13 SRCR domains separated
by short SIDs rich in serine and threonine. To the C-terminal
end of the SCRC domains and SIDs, one zona pellucida and
two CUB (complement protein subcomponents C1r/C1s,
urchin embryonic growth factor and bone morphogenetic
protein 1) domains are located, and a putative transmembrane
domain has also been identified [4].
DMBT1 and glycosylation
DMBT1 is a glycoprotein, withmajor glycosylation account-
ing for up to 30% of its dry mass. It contains 14 N-linked
oligosaccharide amino acid triplet sites, and the SIDs have
many serine and threonine locations for O-glycosylation.
Very little information concerning the nature of DMBT1
glycosylation is available. A study of the O-glycosylation
of DMBT1 forms found in human tears has been reported
[11], but no information is available for the gastrointestinal
forms of DMBT1, and the potential roles for glycosylation
have not been reported or examined with regard to tissue
origin, normal function or pathological significance. Our
present work is designed to address the question of DMBT1
glycosylation against the background of known defects, that
have been identified in well-characterized, cultured human
CRC cell lines and tissues from patients with tumours at
different stages of the adenoma–carcinoma sequence.
Protective functions at the mucosal
surface and in colorectal neoplasia:
a role for DMBT1
We have examined the role of secreted and membrane-
associatedmucins of theMUC gene family in gastrointestinal
disease and, in particular, in the process of malignant trans-
formation [6]. Neoplastic transformation in the colorectum
has been characterized in terms of the adenoma–carcinoma
sequence [12], and a cultured cell model (PC/AA) has been
described and shown to represent stages in the progression to
cancer through the adenoma–carcinoma sequence [5]. These
includepre-malignant andmalignant stages originating froma
single colonic tubular adenomawithmild dysplasia and show
altered O-glycosylation through the progression to adeno-
carcinoma and mucinous carcinoma phenotypes [13,14]. We
have used this model to examine the significance of MUC
gene expression and the glycosylation patterns that are as-
sociated with progression to adenocarcinoma and mucinous
carcinomaphenotypes [13,14]. Independent support for a role
of MUC genes in the development of intestinal cancers has
recently come from study of a Muc2-knockout mouse [7].
This work has shown that loss of the major secretory mucin
gene (Muc2) leads to the appearance of adenocarcinomas in
the intestine. Our own work has shown that this gene is
down-regulated in the development of the adenocarcinoma
phenotype [13,14]. A role for MUC2 glycosylation in neo-
plastic transformation is implicated by these studies, but has
not yet been examined in any detail.
DMBT1 has mucin-like properties and may share some
biological functions with these molecules. The interrelation-
ship of DMBT1 to the mucosal barrier is not clear. A normal
functional role for the molecule has not yet been demon-
strated, and the significance of the abundant glycosylation
remains to be characterized and examined for functional
importance.
Preliminary evidence for glycosylated
DMBT1 in colorectal cells during malignant
transformation
Cells from the PC/AA cultured cell model of the adenoma–
carcinoma sequence were grown as described previously
[13,14]. The cell layer from three cell lines PC/AA (non-
tumorigenic), AA/C1 (non-tumorigenic) and SB10C (tum-
origenic in nude mice) were extracted with 6 M GdmCl
(guanidinium chloride) and subjected to isopycnic density
gradient centrifugation in 4 MGdmCl/CsCl. Reactivity with
the anti-DMBT1h12 serum [10]was seen over a broad density
range (1.32–1.42 g/ml) (Figure 1), which overlapped with the
gel-forming mucins (1.35–1.55 g/ml). These results indicate
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Figure 1 Density gradient centrifugation of PC/AA, C1 and 10C
cell lines and detection of DMBT1
The cell layer was solubilized in 6 M GdmCl containing proteinase
inhibitors and subjected to isopycnic density gradient centrifugation in
4 M GdmCl/CsCl [13]. After centrifugation, the tubes were emptied from
the top (the light end of the gradient density, approx. 1.2 g/ml), and
fractions were assayed for DMBT1 using the DMBT1h12 antiserum [10],
as slot blots.
that DMBT1 is expressed throughout the progression to
malignancy in this model of CRC transformation. In addi-
tion, DMBT1 remains O-glycosylated, in contrast with the
mucins ([13]; and C. Robbe and A. Corfield, unpublished
work), implicating a selective pattern of molecular glycosyl-
ation in these cell lines.
Further support for the pattern of DMBT1 expression was
obtained from a series of patientswith adenomas of increasing
malignant potential (tubular, tubulovillous and villous ade-
nomas), where increased DMBT1 immunoreactivity was
detected relative to normal controls. We have demonstrated
previously the loss of MUC2 and appearance of MUC5AC
in such adenomas [15]. These results are contrary to reports
of down-regulatedDMBT1mRNA levels in CRC (reviewed
in [4]).
Conclusions and perspective
The role of DMBT1 in normal colorectal mucosa and the
nature of cancer-related changes remain to be clarified.
The initial claims of down-regulation in CRC are not sup-
ported in the initial studies presented in this review using
the PC/AA cultured cell culture model of the adenoma–
carcinoma sequence and in individual adenoma patients.
However, it should be emphasized that these are the initial
studies in the colorectal system, and that the use of the
cultured cells appears to be a valuable asset in future work.
Closer analysis of the molecular properties of DMBT1 and,
in particular, its glycosylation patterns during the adenoma–
carcinoma sequence in the colorectum, is currently in pro-
gress.
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